Results for “ ”

Entry Author Date Location
Zentalis Upsizes IPO, Raising $165M for Cancer Drug Clinical Trials 04/03/20 New York
Bio Roundup: Biotech Billions, COVID-19 R&D, Zolgensma’s Path & More 04/03/20 National
Celularity to Test Natural Killer Cell Therapy for Cancer Against COVID 04/02/20 National
Aspen Neuro Adds $70M to Test Parkinson’s Cell Therapy in the Clinic 04/01/20 San Diego
Axsome Plans to Try Again After Failure in Treatment-Resistant Depression 03/30/20 New York
Bio Roundup: Clinical Trials Paused, New MS Drug, Kallyope’s Cash & More 03/27/20 National
FDA Approves Bristol Myers MS Drug, But Pandemic Will Delay Launch 03/26/20 New York
Oncology Needs Combo Therapies & More Data Analysis, Says Bio-Europe Spring Panel 03/26/20 Boston
Kallyope Gains $112M to Move “Gut-Brain Axis” Programs to the Clinic 03/25/20 New York
Palforzia Peanut Allergy Immunotherapy: Aimmune CEO on REMS, Manufacturing 03/24/20 National
Investors Shaken by Coronavirus Sow Seeds of M&A, Financing Slowdown 03/23/20 National
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes 03/23/20 Europe
Bio Roundup: Coronavirus Diagnostics, Therapeutics, Vaccines & More 03/20/20 National
As the Commercial Real Estate Market Slumps, Look for a More Tenant-Friendly Future 03/19/20 Boston
Bio Roundup: Pandemic Declared, Rubius Restarts, Kymera’s Cash & More 03/13/20 National
Kymera Closes $102M Round to Bring Protein-Busting Drugs to the Clinic 03/12/20 Boston
Cushing’s Disease Drug That Novartis Sold to Recordati Nabs FDA Nod 03/09/20 Europe
Zentalis Leads a Trio of Biotechs Charting a Course for Wall Street 03/09/20 New York
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More 03/06/20 National
Melinta’s Chapter 11 Auction Draws No Bids, Deerfield to Get Assets 03/04/20 New York
National Xconomy Awards Now Accepting Nominations for the Best in Biotech 03/03/20 National
Xilio Unveils New Name, $100M to Bring Targeted Cancer Drugs to Clinic 03/02/20 Boston
Bio Roundup: COVID-19 Trials, Esperion’s Approvals, NASH News & More 02/28/20 National
Passage Bio’s IPO Raises $216M to Fund Gene Therapy Studies 02/28/20 National
Biohaven’s Migraine Pill Is the Latest CGRP Drug to Win the FDA’s OK 02/27/20 New York
Esperion’s FDA-Approved Cholesterol Drug Priced Even Lower Than Expected 02/24/20 Detroit Ann Arbor
NGM Bio’s NASH Drug Shows Promise, Shares Rise on Early Phase 2 Data 02/24/20 San Francisco
Lundbeck’s Alder Bio Bet Pays Off With FDA Approval of Migraine Drug 02/23/20 National
Bio Roundup: Agile Approval, Coronavirus Collabs, Spruce’s $88M & More 02/21/20 National
Five Prime, Bristol Pancreatic Cancer Drug Combo Fails Phase 2 Test 02/18/20 San Francisco
Page 1 of 295 next page »